| Amanda Jean Werneke, APRN-CRNA | |
|
1200 E Pecan St, Altus, OK 73521-6192 | |
| (580) 379-5860 | |
| (580) 379-5859 |
| Full Name | Amanda Jean Werneke |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 6 Years |
| Location | 1200 E Pecan St, Altus, Oklahoma |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1295229623 | NPI | - | NPPES |
| 200773860A | Medicaid | OK |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 106409 (Oklahoma) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| St Mary's Regional Medical Center | Enid, OK | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Emergenchealth Pllc | 1355606641 | 585 |
News Archive
Obsessive-Compulsive Disorder is a disorder of the brain where people experience obsessive thoughts, images, ideas or impulses – and they can't get past them. The day-to-day existence for severe OCD sufferers is dire. Untreated, they lead lives of self-punishment, fear and isolation that can result in job loss, broken families, bankruptcy and in some cases death.
In response to the COVID-19 pandemic, researchers from the Massachusetts Institute of Technology have published a pair of studies in a COVID-19 special issue of the Harvard Data Science Review, freely available via open access, describing new methods for accelerating drug approvals during pandemics and for providing more accurate measures of the probabilities of success for clinical trials of vaccines and other anti-infective therapies.
Arrowhead Research Corporation today announced that it has signed an option agreement with The University of Texas MD Anderson Cancer Center to negotiate a license in a defined field to a class of compounds that is believed to kill fat tissue by specifically targeting the blood vessels that supply it. The technology was developed in the laboratory of Drs. Renata Pasqualini and Wadih Arap at MD Anderson in Houston, Texas.
Protalex, Inc., a clinical stage biopharmaceutical company engaged in developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, today announced the dosing of the first patient in a multicenter Phase 1b clinical study of PRTX-100 in adult patients with active Rheumatoid Arthritis (RA). The study is being conducted in South Africa.
› Verified 2 days ago
| Entity Name | Emergenchealth Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1467970897 PECOS PAC ID: 1355606641 Enrollment ID: O20190618003098 |
News Archive
Obsessive-Compulsive Disorder is a disorder of the brain where people experience obsessive thoughts, images, ideas or impulses – and they can't get past them. The day-to-day existence for severe OCD sufferers is dire. Untreated, they lead lives of self-punishment, fear and isolation that can result in job loss, broken families, bankruptcy and in some cases death.
In response to the COVID-19 pandemic, researchers from the Massachusetts Institute of Technology have published a pair of studies in a COVID-19 special issue of the Harvard Data Science Review, freely available via open access, describing new methods for accelerating drug approvals during pandemics and for providing more accurate measures of the probabilities of success for clinical trials of vaccines and other anti-infective therapies.
Arrowhead Research Corporation today announced that it has signed an option agreement with The University of Texas MD Anderson Cancer Center to negotiate a license in a defined field to a class of compounds that is believed to kill fat tissue by specifically targeting the blood vessels that supply it. The technology was developed in the laboratory of Drs. Renata Pasqualini and Wadih Arap at MD Anderson in Houston, Texas.
Protalex, Inc., a clinical stage biopharmaceutical company engaged in developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, today announced the dosing of the first patient in a multicenter Phase 1b clinical study of PRTX-100 in adult patients with active Rheumatoid Arthritis (RA). The study is being conducted in South Africa.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Amanda Jean Werneke, APRN-CRNA 1200 E Pecan St, Altus, OK 73521-6192 Ph: (580) 379-5860 | Amanda Jean Werneke, APRN-CRNA 1200 E Pecan St, Altus, OK 73521-6192 Ph: (580) 379-5860 |
News Archive
Obsessive-Compulsive Disorder is a disorder of the brain where people experience obsessive thoughts, images, ideas or impulses – and they can't get past them. The day-to-day existence for severe OCD sufferers is dire. Untreated, they lead lives of self-punishment, fear and isolation that can result in job loss, broken families, bankruptcy and in some cases death.
In response to the COVID-19 pandemic, researchers from the Massachusetts Institute of Technology have published a pair of studies in a COVID-19 special issue of the Harvard Data Science Review, freely available via open access, describing new methods for accelerating drug approvals during pandemics and for providing more accurate measures of the probabilities of success for clinical trials of vaccines and other anti-infective therapies.
Arrowhead Research Corporation today announced that it has signed an option agreement with The University of Texas MD Anderson Cancer Center to negotiate a license in a defined field to a class of compounds that is believed to kill fat tissue by specifically targeting the blood vessels that supply it. The technology was developed in the laboratory of Drs. Renata Pasqualini and Wadih Arap at MD Anderson in Houston, Texas.
Protalex, Inc., a clinical stage biopharmaceutical company engaged in developing a class of biopharmaceutical drugs for treating autoimmune and inflammatory diseases, today announced the dosing of the first patient in a multicenter Phase 1b clinical study of PRTX-100 in adult patients with active Rheumatoid Arthritis (RA). The study is being conducted in South Africa.
› Verified 2 days ago
Mr. Michael Orlan Lockhart Jr., CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1200 E Pecan St, Altus, OK 73521 Phone: 580-379-5860 Fax: 580-379-5859 | |
Frances Kay Christopher, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 1200 E Pecan St, Altus, OK 73521 Phone: 580-482-4781 Fax: 580-481-2345 | |
Jessica Lanae Poe, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1200 E Pecan St, Altus, OK 73521 Phone: 803-795-8605 Fax: 580-379-5859 | |
Mr. Mark Andrew Waterman, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1200 E Pecan St, Altus, OK 73521 Phone: 580-379-5860 | |
Johnny J Sacco, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1200 E Pecan St, Altus, OK 73521 Phone: 580-379-5000 Fax: 580-379-5509 | |
Mark Vincent Vadney, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 1200 E Pecan St, Altus, OK 73521 Phone: 580-482-4781 Fax: 580-481-2345 |